封面
市场调查报告书
商品编码
1611942

癌症诊断中的人工智慧市场:按组成部分、部署、癌症类型和最终用户 - 2025-2030 年全球预测

AI in Cancer Diagnostics Market by Component (Hardware, Services, Software), Deployment (Cloud, On-Premise), Cancer Type, End-user - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年,癌症诊断领域的人工智慧市场价值为2.2038亿美元,预计到2024年将达到2.6628亿美元,复合年增长率为21.52%,到2030年将达到8.625亿美元。

人工智慧在癌症诊断中的范围涵盖先进演算法和机器学习技术的集成,以提高早期检测、诊断准确性和个人化治疗策略。对人工智慧的需求源于日益增加的癌症负担以及对更准确、更快速的诊断方法的需求。治疗范围从影像分析到预测治疗结果,对医院、研究机构和诊断实验室等最终用户产生重大影响。人工智慧技术进步、医疗保健支出增加以及个人化医疗意识不断增强推动了市场成长。然而,资料隐私问题、高成本和缺乏标准化法规构成了重大挑战。儘管存在这些障碍,新兴商机包括开发用于即时癌症检测的人工智慧驱动工具以及人工智慧与其他技术(例如用于综合诊断的基因组学)的整合。鼓励公司投资研究合作,以提高人工智慧模型对不同人群的准确性和适用性,并解决当前的偏见和限制。创新机会在于建立人工智慧系统,利用巨量资料进行预测分析、简化诊断过程中的工作流程以及改善患者治疗结果。此外,建构人工智慧平台,促进医疗保健提供者之间的资料共用,同时确保患者机密性,并有可能彻底改变协作照护模式。检查人工智慧的道德使用和透明的人工智慧使用者介面可以进一步提高信任和采用率。在快速的技术进步和不断变化的医疗保健需求的推动下,市场充满活力和竞争,要求相关人员保持敏捷并应对新兴趋势。结合技术创新、合规性和策略性伙伴关係关係的整合策略可以释放人工智慧在癌症诊断方面的巨大潜力,并为这一重要领域提供显着的成长和发展机会。

主要市场统计
基准年[2023] 22038万美元
预测年份 [2024] 26628万美元
预测年份 [2030] 8.625 亿美元
复合年增长率(%) 21.52%

市场动态:快速发展的癌症诊断人工智慧市场的关键市场洞察

供需的动态交互作用正在改变癌症诊断的人工智慧市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险,同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 世界人口癌症盛行率
    • 扩大全球癌症筛检计画的采用
    • 快速转向非侵入性癌症诊断
  • 市场限制因素
    • 高成本且缺乏训练有素的肿瘤科医生
  • 市场机会
    • 提高癌症诊断技术
    • 政府投资人工智慧在癌症诊断和治疗的应用
  • 市场挑战
    • 容易遭受网路攻击和资料外洩

波特五力:引领癌症诊断人工智慧市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势,解决弱点并避免潜在的挑战,从而确保更强大的市场地位。

PESTLE分析:了解外部对癌症诊断市场人工智慧的影响

外部宏观环境因素在塑造癌症诊断市场人工智慧的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素,公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化,并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症诊断AI市场的竞争状况

对癌症诊断市场中人工智慧的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势,为供应商提供了製定策略决策所需的见解,以应对日益激烈的竞争。

FPNV 癌症诊断市场AI厂商定位矩阵绩效评估

FPNV 定位矩阵是评估癌症诊断​​市场人工智慧供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商,从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商,以确定最能满足您的策略目标的合作伙伴和解决方案。

为策略分析和癌症诊断建议绘製人工智慧市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说,对癌症诊断市场中的人工智慧进行策略分析至关重要。透过审查关键资源、能力和绩效指标,公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战,利用新的商机并取得长期成功。

本报告对市场进行了全面分析,涵盖关键重点领域:

1. 市场渗透率:对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓:辨识新兴市场的成长机会,评估现有领域的扩张潜力,并提供未来成长的策略蓝图。

3. 市场多元化:分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报:彻底分析竞争格局,检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新:重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题,以帮助相关人员做出明智的决策:

1.目前的市场规模和未来的成长预测是多少?

2. 哪些产品、区隔市场和地区提供最佳投资机会?

3.塑造市场的主要技术趋势和监管影响是什么?

4.主要厂商的市场占有率和竞争地位如何?

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么?

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界人口癌症发生率
      • 全球多个癌症筛检计画招募人数激增
      • 快速过渡到非侵入性癌症诊断
    • 抑制因素
      • 成本高且缺乏训练有素的肿瘤科医生
    • 机会
      • 癌症诊断的技术进步
      • 政府投资人工智慧在癌症诊断和治疗的应用
    • 任务
      • 容易遭受网路攻击和资料外洩
  • 市场区隔分析
    • 组件:大容量测试中心更喜欢能够以最小错误执行大规模资料处理的先进硬体。
    • 癌症类型:脑肿瘤的复杂性和对肿瘤准确分类的需求正在增加基于人工智慧的诊断的重要性。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症诊断中的人工智慧市场:按组成部分

  • 硬体
  • 服务
  • 软体

第七章癌症诊断中的人工智慧市场:按发展划分

  • 本地

第八章以癌症类型诊断癌症的人工智慧市场

  • 脑肿瘤
  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 摄护腺癌
  • 皮肤癌

第九章癌症诊断中的人工智慧市场:按最终用户划分

  • 癌症中心
  • 医院

第10章:美洲癌症诊断的人工智慧市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区癌症诊断人工智慧市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章:欧洲、中东和非洲癌症诊断的人工智慧市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵,2023
  • 竞争情境分析
    • Okin 与默沙东合作开发利用人工智慧的癌症诊断方法
    • ConcertAI 宣布与癌症中心达成协议,透过人工智慧驱动的影像解决方案加速并转变精准肿瘤学
    • 罗氏与 Ibex 和 Amazon Web Services 合作,加速部署人工智慧数位病理解决方案,帮助改善癌症诊断
  • 战略分析和建议

公司名单

  • Aiosyn BV
  • Cancer Center.ai
  • ContextVision AB
  • Deep Bio Inc.
  • Google LLC by Alphabet Inc.
  • Ibex Medical Analytics Ltd.
  • International Business Machines Corporation
  • Kheiron Medical Technologies Limited
  • Lifebit Biotech Ltd
  • Lunit Inc.
  • Medial EarlySign
  • Microsoft Corporation
  • Mindpeak GmbH
  • Paige AI, Inc.
  • PathAI, Inc.
  • Proscia Inc.
  • Qritive
  • Quantib BV
  • ScreenPoint Medical BV
  • Siemens Healthineers AG
  • Tempus Labs, Inc.
  • Therapixel
  • Visiopharm A/S
  • Viz.ai
  • Xavor Corporation
Product Code: MRR-B16853776A7C

The AI in Cancer Diagnostics Market was valued at USD 220.38 million in 2023, expected to reach USD 266.28 million in 2024, and is projected to grow at a CAGR of 21.52%, to USD 862.50 million by 2030.

The scope of AI in cancer diagnostics spans the integration of advanced algorithms and machine learning techniques to enhance early detection, diagnosis accuracy, and personalized treatment strategies. The necessity of AI arises from the growing cancer burden and the need for more precise and faster diagnostic methods. Applications range from image analysis to predicting treatment outcomes, significantly impacting end-users such as hospitals, research institutions, and diagnostic labs. Market growth is fueled by technological advancements in AI, increased healthcare expenditure, and growing awareness of personalized medicine. However, data privacy concerns, high costs, and lack of standardized regulations pose significant challenges. Despite these barriers, the latest opportunities include developing AI-driven tools for real-time cancer detection and integrating AI with other technologies such as genomics for comprehensive diagnostics. Companies are recommended to invest in research collaborations to enhance AI models' accuracy and applicability across diverse populations, addressing current biases and limitations. Innovation opportunities lie in creating AI systems that utilize big data for predictive analytics, enhancing workflow efficiency in diagnostic processes, and improving patient outcomes. Additionally, there is a promising avenue for creating AI platforms that facilitate data sharing among healthcare providers while ensuring patient confidentiality, potentially revolutionizing collaborative care models. Research into ethical AI usage and transparent AI user interfaces could further enhance trust and adoption rates. The market is dynamic yet competitive, driven by rapid technological progress and evolving healthcare needs, requiring stakeholders to stay agile and responsive to new trends. An integrated strategy combining technological innovation, compliance adherence, and strategic partnerships can unlock significant potential in AI for cancer diagnostics, offering substantial growth and development opportunities in this crucial sector.

KEY MARKET STATISTICS
Base Year [2023] USD 220.38 million
Estimated Year [2024] USD 266.28 million
Forecast Year [2030] USD 862.50 million
CAGR (%) 21.52%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving AI in Cancer Diagnostics Market

The AI in Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cancer among the global population
    • Proliferating adoption in several cancer screening programs worldwide
    • Exponential shift towards non-invasive cancer diagnosis
  • Market Restraints
    • High cost and shortage of trained oncologists
  • Market Opportunities
    • Technological improvements in cancer diagnostics
    • Government investments in using AI in cancer diagnostics and treatments
  • Market Challenges
    • Vulnerability to cyberattacks and data breaches

Porter's Five Forces: A Strategic Tool for Navigating the AI in Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the AI in Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the AI in Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the AI in Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the AI in Cancer Diagnostics Market

A detailed market share analysis in the AI in Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the AI in Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the AI in Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the AI in Cancer Diagnostics Market

A strategic analysis of the AI in Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.

Market Segmentation & Coverage

This research report categorizes the AI in Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Hardware, Services, and Software.
  • Based on Deployment, market is studied across Cloud and On-Premise.
  • Based on Cancer Type, market is studied across Brain Tumor, Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Skin Cancer.
  • Based on End-user, market is studied across Cancer Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancer among the global population
      • 5.1.1.2. Proliferating adoption in several cancer screening programs worldwide
      • 5.1.1.3. Exponential shift towards non-invasive cancer diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and shortage of trained oncologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological improvements in cancer diagnostics
      • 5.1.3.2. Government investments in using AI in cancer diagnostics and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Vulnerability to cyberattacks and data breaches
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: High-volume testing centers prefer advanced hardware that can handle large-scale data processing with minimal error
    • 5.2.2. Cancer Type: Rising significance of AI-driven diagnostic for brain tumors due to complexity & critical need for precise tumor classification
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. AI in Cancer Diagnostics Market, by Component

  • 6.1. Introduction
  • 6.2. Hardware
  • 6.3. Services
  • 6.4. Software

7. AI in Cancer Diagnostics Market, by Deployment

  • 7.1. Introduction
  • 7.2. Cloud
  • 7.3. On-Premise

8. AI in Cancer Diagnostics Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Brain Tumor
  • 8.3. Breast Cancer
  • 8.4. Colorectal Cancer
  • 8.5. Lung Cancer
  • 8.6. Prostate Cancer
  • 8.7. Skin Cancer

9. AI in Cancer Diagnostics Market, by End-user

  • 9.1. Introduction
  • 9.2. Cancer Centers
  • 9.3. Hospitals

10. Americas AI in Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific AI in Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa AI in Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer
    • 13.3.2. ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions
    • 13.3.3. Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aiosyn B.V.
  • 2. Cancer Center.ai
  • 3. ContextVision AB
  • 4. Deep Bio Inc.
  • 5. Google LLC by Alphabet Inc.
  • 6. Ibex Medical Analytics Ltd.
  • 7. International Business Machines Corporation
  • 8. Kheiron Medical Technologies Limited
  • 9. Lifebit Biotech Ltd
  • 10. Lunit Inc.
  • 11. Medial EarlySign
  • 12. Microsoft Corporation
  • 13. Mindpeak GmbH
  • 14. Paige AI, Inc.
  • 15. PathAI, Inc.
  • 16. Proscia Inc.
  • 17. Qritive
  • 18. Quantib B.V.
  • 19. ScreenPoint Medical BV
  • 20. Siemens Healthineers AG
  • 21. Tempus Labs, Inc.
  • 22. Therapixel
  • 23. Visiopharm A/S
  • 24. Viz.ai
  • 25. Xavor Corporation

LIST OF FIGURES

  • FIGURE 1. AI IN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. AI IN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AI IN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AI IN CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023